Press release
According to DelveInsight, the Non Alcoholic Fatty Liver Disease Market in 7MM is expected to witness a major change in the study period 2019-2032
DelveInsight's "Non Alcoholic Fatty Liver Disease Market" report provides a thorough comprehension of the Non Alcoholic Fatty Liver Disease, historical and forecasted epidemiology, and the Non Alcoholic Fatty Liver Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Non Alcoholic Fatty Liver Disease market report also proffers an analysis of the current Non Alcoholic Fatty Liver Disease treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.The Non Alcoholic Fatty Liver Disease market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
Key takeaways from the Non Alcoholic Fatty Liver Disease Market Report
• According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It's estimated that about 25% of adults in the U.S. have NAFLD. Of those with NAFLD, about 20% have NASH (5% of adults in the US). Most people with NAFLD have simply fatty liver.
• A study by Golabi et al. (2015), 3,271 NHANES-III participants and the prevalence rates from NAFLD were 40.3% and 39.2% among 60-74 and >74 years old. Among aged 60-74, the risks for 5-year and 10-year all-cause mortality were associated with presence of NAFLD for 5-year and 1.22.
• Non Alcoholic Fatty Liver Disease Market Companies included Altimmune Inc, Merck Sharp & Dohme LLC, DSM Nutritional Products Inc, Indiana University, Better Therapeutics, Arizona Liver Health, Terns Inc, Alnylam Pharmaceuticals, Genentech, Oramed Ltd, and several others.
• Non Alcoholic Fatty Liver Disease Market Therapies included ALT-801, Placebo, BT-NCBT-00X, TERN-201, ALN-HSD, Icosabutate, BFKB8488A, and several others.
Download Sample Report- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Non Alcoholic Fatty Liver Disease Overview
Nonalcoholic fatty liver disease (NAFLD) refers to a group of liver disorders that affect persons who use little to no alcohol. The fundamental feature of NAFLD, as the name suggests, is an excess of fat deposited in liver cells. Nonalcoholic fatty liver disease is becoming more frequent over the world, particularly in Western countries. It is the most common type of chronic liver disease in the United States, affecting almost one-quarter of the population.
Nonalcoholic fatty liver disease Epidemiology Insights
Nonalcoholic fatty liver disease develops in four main stages. 1) Simple fatty liver (steatosis) (NAFL)-a largely harmless build-up of fat in the liver cells that may only be diagnosed during tests carried out for another reason, 2) non-alcoholic steatohepatitis (NASH) - a more serious form of NAFLD, where the liver has become inflamed, 3) fibrosis-where persistent inflammation causes scar tissue around the liver and nearby blood vessels, but the liver is still able to function normally, and 4) cirrhosis - the most severe stage, occurring after years of inflammation.
Nonalcoholic fatty liver disease Epidemiology Segmentation in the 7MM
• Total Nonalcoholic fatty liver disease Prevalent Cases
• Nonalcoholic fatty liver disease Age-specific Prevalent Cases
• Nonalcoholic fatty liver disease Stage-specific Prevalent Cases
• Nonalcoholic fatty liver disease Gender-specific Prevalent Cases
• Nonalcoholic fatty liver disease Diagnosed and Treatable Cases
Nonalcoholic fatty liver disease Market
Nonalcoholic fatty liver disease is part of the metabolic syndrome characterized by diabetes, or pre-diabetes (insulin resistance), being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. Not all patients have all the manifestations of the metabolic syndrome. Less is known about what causes NASH to develop. Researchers are focusing on several factors that may contribute to the development of NASH. These include oxidative stress (imbalance between pro-oxidant and anti-oxidant chemicals that lead to liver cell damage); production and release of toxic inflammatory proteins (cytokines) by the patient's own inflammatory cells, liver cells, or fat cells; liver cell necrosis or death, called apoptosis; adipose tissue (fat tissue) inflammation and infiltration by white blood cells; and gut microbiota (intestinal bacteria) which may play a role in liver inflammation.
Nonalcoholic fatty liver disease Market Insights
About 2 to 5 percent of adult Americans and up to 20 percent of those who are obese may suffer from the more severe condition NASH. The number of children who have NASH is not known. The presence of type 2 diabetes and other conditions associated with insulin resistance, such as polycystic ovarian syndrome are known risk factors for the development of fatty liver and NASH.
Scope of the Non Alcoholic Fatty Liver Disease Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 11 Years
• Non Alcoholic Fatty Liver Disease Market Companies included Altimmune Inc, Merck Sharp & Dohme LLC, DSM Nutritional Products Inc, Indiana University, Better Therapeutics, Arizona Liver Health, Terns Inc, Alnylam Pharmaceuticals, Genentech, Oramed Ltd, and several others.
• Non Alcoholic Fatty Liver Disease Market Therapies included ALT-801, Placebo, BT-NCBT-00X, TERN-201, ALN-HSD, Icosabutate, BFKB8488A, and several others.
• Market Drivers and Barriers
• KOL Views
Request Sample Report- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Non Alcoholic Fatty Liver Disease Executive Summary
3. Competitive Intelligence Analysis for Non-Alcoholic Fatty Liver Disease
4. Non Alcoholic Fatty Liver Disease Market Overview at a Glance
5. Non Alcoholic Fatty Liver Disease Disease Background and Overview
6. Patient Journey
7. Non Alcoholic Fatty Liver Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Non Alcoholic Fatty Liver Disease Unmet Needs
10. Key Endpoints of Non Alcoholic Fatty Liver Disease Treatment
11. Non Alcoholic Fatty Liver Disease Marketed Products
12. Non Alcoholic Fatty Liver Disease Emerging Therapies
13. Non Alcoholic Fatty Liver Disease Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Non Alcoholic Fatty Liver Disease Market Outlook
16. Access and Reimbursement Overview of Non Alcoholic Fatty Liver Disease
17. KOL Views
18. Non Alcoholic Fatty Liver Disease Market Drivers
19. Non Alcoholic Fatty Liver Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Do you have any query related to the report? Just speak to analyst- https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Contact Us
Yash
info@delveinsight.com
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release According to DelveInsight, the Non Alcoholic Fatty Liver Disease Market in 7MM is expected to witness a major change in the study period 2019-2032 here
News-ID: 2725496 • Views: …
More Releases from DelveInsight Business Research

Tonic clonic Seizure Market to Experience Notable Growth in Forecast Span by 203 …
DelveInsight's "Tonic clonic Seizure Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Tonic clonic Seizure, historical and forecasted epidemiology as well as the Tonic clonic Seizure market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Tonic clonic Seizure, offering comprehensive insights into the Tonic clonic Seizure revenue trends,…

Panic Disorder Market Insights Highlight Expanding Outlook Till 2032, DelveInsig …
DelveInsight's "Panic Disorder Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Panic Disorder, historical and forecasted epidemiology as well as the Panic Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Panic Disorder, offering comprehensive insights into the Panic Disorder revenue trends, prevalence, and treatment landscape. The…

Chronic Pain Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight …
DelveInsight's "Chronic Pain Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Market Forecast
https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…

Chemotherapy-induced Thrombocytopenia Market Positioned for Accelerated Developm …
DelveInsight's "Chemotherapy-induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Chemotherapy-induced Thrombocytopenia, historical and forecasted epidemiology as well as the Chemotherapy-induced Thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chemotherapy-induced Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy-induced Thrombocytopenia Market Forecast
https://www.delveinsight.com/sample-request/chemotherapy-induced-thrombocytopenia-cit-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key…
More Releases for Liver
Acute on Chronic Liver Failure Market Impacts Liver Disease Patients By 2031
Global Acute On Chronic Liver Failure Market reached at a CAGR during the forecast period 2024-2031.
Acute On Chronic Liver Failure Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models, financial outcomes, and growth strategies. It serves as a concise yet insightful…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…